Skip NavigationSkip to Content

Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history

  1. Author:
    de Andrade, Kelvin Cesar
    Mirabello, Lisa
    Stewart, Douglas R.
    Karlins, Eric
    Koster, Roelof
    Wang, Mingyi
    Gapstur, Susan M.
    Gaudet, Mia M.
    Freedman, Neal D.
    Landi, Maria Teresa
    Lemonnier, Nathanael
    Hainaut, Pierre
    Savage, Sharon A.
    Achatz, Maria Isabel
  2. Author Address

    NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA.AC Camargo Canc Ctr, Int Res Ctr, Sao Paulo, Brazil.NCI, Canc Gen Res Lab, Div Canc Epidemiol & Genet, Leidos Biomed Res Inc,Dept Hlth & Human Serv, Bethesda, MD 20892 USA.NCI, Lab Genet Susceptibil, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA.Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.NCI, Metab Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA.NCI, Integrat Tumor Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA.Univ Grenoble Alpes, Inst Adv Biosci, Inserm, U1209,CNRS,UMR 5309, Allee Alpes, La Tronche, France.
    1. Year: 2017
    2. Date: Dec
  1. Journal: Human Mutation
  2. WILEY,
    1. 38
    2. 12
    3. Pages: 1723-1730
  3. Type of Article: Article
  4. ISSN: 1059-7794
  1. Abstract:

    Li-Fraumeni syndrome (LFS) is an autosomal-dominant cancer predisposition disorder associated with pathogenic germline variants in TP53, with a high penetrance over an individual's lifetime. The actual population prevalence of pathogenic germline TP53 mutations is still unclear, most likely due to biased selection of cancer affected families. The aim of this study was to estimate the population prevalence of potentially pathogenic TP53 exonic variants in three sequencing databases, totaling 63,983 unrelated individuals. Potential pathogenicity was defined using an original algorithm combining bioinformatic prediction tools, suggested clinical significance, and functional data. We identified 34 different potentially pathogenic TP53 variants in 131 out of 63,983 individuals (0.2%). Twenty-eight (82%) of these variants fell within the DNA-binding domain of TP53, with an enrichment for specific variants that were not previously identified as LFS mutation hotspots, such as the p.R290H and p.N235S variants. Our findings reveal that the population prevalence of potentially pathogenic TP53 variants may be up to 10 times higher than previously estimated from family-based studies. These results point to the need for further studies aimed at evaluating cancer penetrance modifiers as well as the risk associated between cancer and rare TP53 variants.

    See More

External Sources

  1. DOI: 10.1002/humu.23320
  2. PMID: 28861920
  3. WOS: 000414241200009

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel